Literature DB >> 22772445

Mutation at positively selected positions in the binding site for HLA-C shows that KIR2DL1 is a more refined but less adaptable NK cell receptor than KIR2DL3.

Hugo G Hilton1, Luca Vago, Anastazia M Older Aguilar, Achim K Moesta, Thorsten Graef, Laurent Abi-Rached, Paul J Norman, Lisbeth A Guethlein, Katharina Fleischhauer, Peter Parham.   

Abstract

Through recognition of HLA class I, killer cell Ig-like receptors (KIR) modulate NK cell functions in human immunity and reproduction. Although a minority of HLA-A and -B allotypes are KIR ligands, HLA-C allotypes dominate this regulation, because they all carry either the C1 epitope recognized by KIR2DL2/3 or the C2 epitope recognized by KIR2DL1. The C1 epitope and C1-specific KIR evolved first, followed several million years later by the C2 epitope and C2-specific KIR. Strong, varying selection pressure on NK cell functions drove the diversification and divergence of hominid KIR, with six positions in the HLA class I binding site of KIR being targets for positive diversifying selection. Introducing each naturally occurring residue at these positions into KIR2DL1 and KIR2DL3 produced 38 point mutants that were tested for binding to 95 HLA- A, -B, and -C allotypes. Modulating specificity for HLA-C is position 44, whereas positions 71 and 131 control cross-reactivity with HLA-A*11:02. Dominating avidity modulation is position 70, with lesser contributions from positions 68 and 182. KIR2DL3 has lower avidity and broader specificity than KIR2DL1. Mutation could increase the avidity and change the specificity of KIR2DL3, whereas KIR2DL1 specificity was resistant to mutation, and its avidity could only be lowered. The contrasting inflexibility of KIR2DL1 and adaptability of KIR2DL3 fit with C2-specific KIR having evolved from C1-specific KIR, and not vice versa. Substitutions restricted to activating KIR all reduced the avidity of KIR2DL1 and KIR2DL3, further evidence that activating KIR function often becomes subject to selective attenuation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22772445      PMCID: PMC3439511          DOI: 10.4049/jimmunol.1100431

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  76 in total

1.  Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer.

Authors:  N Wagtmann; S Rajagopalan; C C Winter; M Peruzzi; E O Long
Journal:  Immunity       Date:  1995-12       Impact factor: 31.745

2.  Nucleotide sequence analysis of the HLA class I region spanning the 237-kb segment around the HLA-B and -C genes.

Authors:  N Mizuki; H Ando; M Kimura; S Ohno; S Miyata; M Yamazaki; H Tashiro; K Watanabe; A Ono; S Taguchi; C Sugawara; Y Fukuzumi; K Okumura; K Goto; M Ishihara; S Nakamura; J Yonemoto; Y Y Kikuti; T Shiina; L Chen; A Ando; T Ikemura; H Inoko
Journal:  Genomics       Date:  1997-05-15       Impact factor: 5.736

3.  The CD94/NKG2-A inhibitory receptor complex is involved in natural killer cell-mediated recognition of cells expressing HLA-G1.

Authors:  J J Pérez-Villar; I Melero; F Navarro; M Carretero; T Bellón; M Llano; M Colonna; D E Geraghty; M López-Botet
Journal:  J Immunol       Date:  1997-06-15       Impact factor: 5.422

4.  HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells.

Authors:  M Colonna; G Borsellino; M Falco; G B Ferrara; J L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

5.  A single amino acid in the p58 killer cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes.

Authors:  C C Winter; E O Long
Journal:  J Immunol       Date:  1997-05-01       Impact factor: 5.422

6.  Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene.

Authors:  M Colonna; T Spies; J L Strominger; E Ciccone; A Moretta; L Moretta; D Pende; O Viale
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-01       Impact factor: 11.205

7.  NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules.

Authors:  V Litwin; J Gumperz; P Parham; J H Phillips; L L Lanier
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

8.  A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells.

Authors:  M Colonna; F Navarro; T Bellón; M Llano; P García; J Samaridis; L Angman; M Cella; M López-Botet
Journal:  J Exp Med       Date:  1997-12-01       Impact factor: 14.307

9.  NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80.

Authors:  M Cella; A Longo; G B Ferrara; J L Strominger; M Colonna
Journal:  J Exp Med       Date:  1994-10-01       Impact factor: 14.307

10.  The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.

Authors:  J E Gumperz; V Litwin; J H Phillips; L L Lanier; P Parham
Journal:  J Exp Med       Date:  1995-03-01       Impact factor: 14.307

View more
  50 in total

1.  Human NK cells maintain licensing status and are subject to killer immunoglobulin-like receptor (KIR) and KIR-ligand inhibition following ex vivo expansion.

Authors:  Wei Wang; Amy K Erbe; Kory A Alderson; Emily Phillips; Mikayla Gallenberger; Jacek Gan; Dario Campana; Jacquelyn A Hank; Paul M Sondel
Journal:  Cancer Immunol Immunother       Date:  2016-07-08       Impact factor: 6.968

2.  Polymorphic HLA-C Receptors Balance the Functional Characteristics of KIR Haplotypes.

Authors:  Hugo G Hilton; Lisbeth A Guethlein; Ana Goyos; Neda Nemat-Gorgani; David A Bushnell; Paul J Norman; Peter Parham
Journal:  J Immunol       Date:  2015-08-26       Impact factor: 5.422

3.  Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.

Authors:  Suliman Y Alomar; Afrah Alkhuriji; Paul Trayhyrn; Abdulkarim Alhetheel; Abdullah Al-Jurayyan; Lamjed Mansour
Journal:  Immunogenetics       Date:  2016-09-15       Impact factor: 2.846

Review 4.  Missing or altered self: human NK cell receptors that recognize HLA-C.

Authors:  Hugo G Hilton; Peter Parham
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

5.  KIR3DS1-Specific D0 Domain Polymorphisms Disrupt KIR3DL1 Surface Expression and HLA Binding.

Authors:  Tiernan J Mulrooney; Aaron C Zhang; Yehuda Goldgur; Jeanette E Boudreau; Katharine C Hsu
Journal:  J Immunol       Date:  2015-06-24       Impact factor: 5.422

6.  Different Selected Mechanisms Attenuated the Inhibitory Interaction of KIR2DL1 with C2+ HLA-C in Two Indigenous Human Populations in Southern Africa.

Authors:  Neda Nemat-Gorgani; Hugo G Hilton; Brenna M Henn; Meng Lin; Christopher R Gignoux; Justin W Myrick; Cedric J Werely; Julie M Granka; Marlo Möller; Eileen G Hoal; Makoto Yawata; Nobuyo Yawata; Lies Boelen; Becca Asquith; Peter Parham; Paul J Norman
Journal:  J Immunol       Date:  2018-03-16       Impact factor: 5.422

Review 7.  Co-evolution of MHC class I and variable NK cell receptors in placental mammals.

Authors:  Lisbeth A Guethlein; Paul J Norman; Hugo G Hilton; Peter Parham
Journal:  Immunol Rev       Date:  2015-09       Impact factor: 12.988

Review 8.  Variable NK cell receptors and their MHC class I ligands in immunity, reproduction and human evolution.

Authors:  Peter Parham; Ashley Moffett
Journal:  Nat Rev Immunol       Date:  2013-01-21       Impact factor: 53.106

9.  Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma.

Authors:  Can Küçük; Xiaozhou Hu; Qiang Gong; Bei Jiang; Adam Cornish; Philippe Gaulard; Timothy McKeithan; Wing C Chan
Journal:  Am J Pathol       Date:  2016-04-07       Impact factor: 4.307

10.  Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia.

Authors:  Sarah Cooley; Daniel J Weisdorf; Lisbeth A Guethlein; John P Klein; Tao Wang; Steven G E Marsh; Stephen Spellman; Michael D Haagenson; Koy Saeturn; Martha Ladner; Elizabeth Trachtenberg; Peter Parham; Jeffrey S Miller
Journal:  J Immunol       Date:  2014-04-18       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.